These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17046312)

  • 1. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.
    Ondo WG; Mejia NI; Hunter CB
    Parkinsonism Relat Disord; 2007 Oct; 13(7):453-4. PubMed ID: 17046312
    [No Abstract]   [Full Text] [Related]  

  • 2. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.
    Ondo WG; Shinawi L; Davidson A; Lai D
    Parkinsonism Relat Disord; 2011 Mar; 17(3):156-9. PubMed ID: 21193343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.
    Keck PE; Hsu HA; Papadakis K; Russo J
    Clin Neuropharmacol; 2009; 32(4):199-204. PubMed ID: 19620854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot efficacy and tolerability trial of memantine for essential tremor.
    Handforth A; Bordelon Y; Frucht SJ; Quesada A
    Clin Neuropharmacol; 2010; 33(5):223-6. PubMed ID: 20838216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
    Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amantadine in the akinetic-rigid variant of Huntington's disease.
    Magnet MK; Bonelli RM; Kapfhammer HP
    Ann Pharmacother; 2004; 38(7-8):1194-6. PubMed ID: 15178736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, flexible-dose study of memantine in major depressive disorder.
    Ferguson JM; Shingleton RN
    Clin Neuropharmacol; 2007; 30(3):136-44. PubMed ID: 17545748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study.
    McArthur AW; Pollock M; Smidt NA
    N Z Med J; 1976 Feb; 83(558):114-6. PubMed ID: 131917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acquired periodic alternating nystagmus with memantine: a case report.
    Kumar A; Thomas S; McLean R; Proudlock FA; Roberts E; Boggild M; Gottlob I
    Clin Neuropharmacol; 2009; 32(2):109-10. PubMed ID: 19512963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine in the treatment of binge eating disorder: an open-label, prospective trial.
    Brennan BP; Roberts JL; Fogarty KV; Reynolds KA; Jonas JM; Hudson JI
    Int J Eat Disord; 2008 Sep; 41(6):520-6. PubMed ID: 18433015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide use of medicines for Alzheimer's disease by community-dwelling persons in Finland.
    Alander J; Lönnroos E; Hartikainen S; Klaukka T
    J Am Geriatr Soc; 2006 Mar; 54(3):557-8. PubMed ID: 16551340
    [No Abstract]   [Full Text] [Related]  

  • 15. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.
    Dubinsky R; Gray C
    Mov Disord; 2006 Apr; 21(4):530-3. PubMed ID: 16258942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting safety of minocycline as neuroprotection in Huntington's disease.
    Reynolds N
    Mov Disord; 2007 Jan; 22(2):292. PubMed ID: 17083098
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of lithium carbonate in the treatment of Huntington's chorea].
    Candalino G; Fragassi NA; Campanella G
    Acta Neurol (Napoli); 1977; 32(6):862-71. PubMed ID: 147006
    [No Abstract]   [Full Text] [Related]  

  • 18. Spontaneous bruising as a possible adverse reaction to memantine.
    Scharf SL; Parikh S; Dillon LC
    Intern Med J; 2005 Sep; 35(9):571-2. PubMed ID: 16105164
    [No Abstract]   [Full Text] [Related]  

  • 19. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C; Hunter C; Davidson A; Jankovic J
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with risperidone and memantine in the treatment of Huntington's disease.
    Cankurtaran ES; Ozalp E; Soygur H; Cakir A
    J Natl Med Assoc; 2006 Aug; 98(8):1353-5. PubMed ID: 16916137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.